This can be dealt with successfully if cognitively normal individuals on standard memory testing are reliably diagnosed as at-risk preclinical AD suitable for preventive BACE1 inhibitor interventions according to genetic predisposition, ALF assessment and related biomarker profiles. The gene discussed is BACE1; the disease is Alzheimer disease.